Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma

[1]  D. Jäger,et al.  Influence of Interferon-Alpha Combined with Chemo (Radio) Therapy on Immunological Parameters in Pancreatic Adenocarcinoma , 2014, International journal of molecular sciences.

[2]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[3]  B. Glimelius,et al.  Adjuvant chemotherapy , 2013, EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.].

[4]  J. Werner,et al.  Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer , 2013, Oncoimmunology.

[5]  P. Kornprat,et al.  Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer , 2013, British Journal of Cancer.

[6]  A. Madrigal,et al.  Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy , 2013, Cellular and Molecular Immunology.

[7]  M. Donia,et al.  Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment , 2012, Cancer Microenvironment.

[8]  D. Jäger,et al.  Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. Mok,et al.  A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma , 2012, Cancer.

[10]  R. Wank,et al.  Activated Monocytes Prime Naïve T Cells Against Autologous Cancer: Vigorous Cancer Destruction In Vitro and In Vivo , 2012, Scandinavian journal of immunology.

[11]  N. Halama,et al.  Predictive Immunological Markers in Oncology , 2012, Front. Immun..

[12]  Christopher M. Clark,et al.  Near eradication of clinically relevant concentrations of human tumor cells by interferon-activated monocytes in vitro. , 2011, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[13]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[14]  H. Friess,et al.  Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. , 2010, JAMA.

[15]  L. Frati,et al.  Immunology of gynecologic neoplasms: analysis of the prognostic significance of the immune status. , 2009, Current Cancer Drug Targets.

[16]  Richard Simon,et al.  The Use of Genomics in Clinical Trial Design , 2008, Clinical Cancer Research.

[17]  Antal Rot,et al.  CCR7 and its ligands: balancing immunity and tolerance , 2008, Nature Reviews Immunology.

[18]  G. Randolph,et al.  Antigen presentation by monocytes and monocyte-derived cells. , 2008, Current opinion in immunology.

[19]  K. Zoon,et al.  Clinical model: interferons activate human monocytes to an eradicative tumor cell level in vitro. , 2007, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[20]  D. Jäger,et al.  Impact of Interferon-α in Combined Chemoradioimmunotherapy for Pancreatic Adenocarcinoma (CapRI): First Data From the Immunomonitoring , 2007, Journal of immunotherapy.

[21]  A. Dalgleish,et al.  Biomarkers for the Development of Cancer Vaccines , 2006, Molecular Diagnosis & Therapy.

[22]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[23]  D. Jäger,et al.  Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): First data from the immunomonitoring , 2006 .

[24]  Richard Bold,et al.  Survival Among Patients with Adenocarcinoma of the Pancreas: A Population-based Study (United States) , 2006, Cancer Causes & Control.

[25]  A. Jimeno,et al.  Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer , 2006, Molecular Cancer Therapeutics.

[26]  E. Tartour,et al.  Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers , 2006, Clinical Cancer Research.

[27]  B. Robinson,et al.  Immunotherapy and chemotherapy — a practical partnership , 2005, Nature Reviews Cancer.

[28]  M. Büchler,et al.  Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  Antonio Lanzavecchia,et al.  Central memory and effector memory T cell subsets: function, generation, and maintenance. , 2004, Annual review of immunology.

[30]  T. Oshikiri,et al.  CD8+ Tumor-Infiltrating Lymphocytes Together with CD4+ Tumor-Infiltrating Lymphocytes and Dendritic Cells Improve the Prognosis of Patients with Pancreatic Adenocarcinoma , 2004, Pancreas.

[31]  M. Oka,et al.  Increased expression of MUC1 in advanced pancreatic cancer , 2003, Journal of Gastroenterology.

[32]  L. Pelosio,et al.  Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. , 2002, Clinical immunology.

[33]  M. Zabel,et al.  Cell-specific regulation of the CD21 gene. , 2001, International immunopharmacology.

[34]  M. Rizzetto,et al.  Predictors of response to interferon therapy , 1996, Digestive Diseases and Sciences.

[35]  J. Ceuppens,et al.  CD80, CD86 and CD40 Provide Accessory Signals in a Multiple‐Step T‐Cell Activation Model , 1996, Immunological reviews.

[36]  E. Levy,et al.  T lymphocyte expression of complement receptor 2 (CR2/CD21): a role in adhesive cell‐cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE) , 1992, Clinical and experimental immunology.

[37]  J. Werner,et al.  Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy , 2013, Cancer Immunology, Immunotherapy.

[38]  T. Eberlein.  Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial , 2008 .

[39]  P. Loehrer.  Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial , 2008 .

[40]  V. Diehl,et al.  Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma – CapRI: study protocol [ISRCTN62866759] , 2005, BMC Cancer.

[41]  D. G. Altman,et al.  Statistical aspects of prognostic factor studies in oncology. , 1994, British Journal of Cancer.